Mylan Laboratories' Prescription: Fool by Numbers
By
Motley Fool Contributors
November 2, 2006
|
On Nov. 1, Mylan Laboratories (NYSE: MYL) released third-quarter earnings for the period ended Sept. 30.
- There was robust top-line and earnings growth compared to the year-ago quarter.
- Mylan's fentanyl transdermal system was the key growth driver, contributing 20% to total revenues.
- Net profit increased 116.8% to $78 million, capitalizing on double-digit revenue growth and greatly improved margins.
- EPS growth was aided by a shrinking share count.
(Figures in millions, except per-share data)
Income Statement Highlights
|
Avg. Est.
|
Q3 2006
|
Q3 2005
|
Change
|
|
Sales
|
$351
|
$366.7
|
$298.0
|
23%
|
|
Net Profit*
|
--
|
$77.5
|
$35.8
|
116.8%
|
|
EPS
|
$0.32
|
$0.36
|
$0.16
|
125%
|
|
Diluted Shares
|
--
|
215.1
|
229.3
|
(6.2%)
|
*Net profit does not include income from discontinued operations.
Get back to basics with a look at the income statement.
Margin Checkup
*Expressed in percentage points.
Margins are the earnings engine. See how they work.
Balance Sheet Highlights
|
Assets
|
Q3 2006
|
Q3 2005
|
Change
|
|
Cash + ST Invest.
|
$611.7
|
$631.5
|
(3.1%)
|
|
Accounts Rec.
|
$252.5
|
$239.0
|
5.7%
|
|
Inventory
|
$303.3
|
$255.4
|
18.8%
|
Learn the ways of the balance sheet.
Cash Flow Highlights
A statement of cash flows was not provided.
Find out why Fools always follow the money.
Related Companies:
-
Barr Pharmaceuticals (NYSE: BRL)
-
Teva Pharmaceutical Industries (Nasdaq: TEVA)
-
Watson Pharmaceutical (NYSE: WPI)
Related Foolishness:
Want to weigh in on Mylan or any other pharmaceuticals? Check out CAPS, The Motley Fool's new stock-picking service, and let your voice be heard!
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.